Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 11;30(5):604-606.
doi: 10.1016/j.chom.2022.04.004.

RTS,S today and tomorrow's science

Nginache Nampota Nkomba  1 , Cristiana Cairo  2 , Miriam K Laufer  3
Affiliations

RTS,S today and tomorrow's science

Nginache Nampota Nkomba et al. Cell Host Microbe. .

Abstract

The first malaria vaccine has been recently approved for children living in malaria-endemic areas. While this is long-awaited and welcome news, the modest efficacy of the vaccine highlights several areas that require further attention. Here, we describe the likely impact of the vaccine and where clinical and basic discovery research will still be required.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

References

    1. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmüller B, et al. (2011). First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med 365, 1863–1875. 10.1056/nejmoa1102287. - DOI - PubMed
    1. Baeza Garcia A, Siu E, Sun T, Exler V, Brito L, Hekele A, Otten G, Augustijn K, Janse CJ, Ulmer JB, et al. (2018). Neutralization of the Plasmodium-encoded MIF ortholog confers protective immunity against malaria infection. Nat. Commun 9, 2714. 10.1038/s41467-018-05041-7. - DOI - PMC - PubMed
    1. Chandramohan D, Zongo I, Sagara I, Cairns M, Yerbanga RS, Diarra M, Nikiema F, Tapily A, Sompougdou F, Issiaka D, et al. (2021). Seasonal malaria vaccination with or without seasonal malaria Chemoprevention. N. Engl. J. Med 385, 1005–1017. 10.1056/nejmoa2026330. - DOI - PubMed
    1. Chitnis CE, Schellenberg D, Vekemans J, Asturias EJ, Bejon P, Collins KA, Crabb BS, Herrera S, Laufer M, Rabinovich NR, et al. (2020). Building momentum for malaria vaccine research and development: key considerations. Malar. J 19, 421. 10.1186/s12936-020-03491-3. - DOI - PMC - PubMed
    1. Datoo MS, Natama MH, Somé A, Traoré O, Rouamba T, Bellamy D, Yameogo P, Valia D, Tegneri M, Ouedraogo F, et al. (2021). Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet 397, 1809–1818. 10.1016/s0140-6736(21)00943-0. - DOI - PMC - PubMed

Substances